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IMMUNE CELL COMPOSITION IN NSCLC TUMORS
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in people in the
United States.1 Once the cancer has metastasized (stage IV), the five-year overall survival rate
decreases to less than 5%.2 Numerous efforts have been conducted to find new forms of therapy
that target these tumor cells. Gamma delta () T cells and CD8+ T cells manifest robust
cytolytic machinery to kill cancerous or virally infected cells. Tumor cells and other immune
cells can inhibit T cell effector function by expressing PD-L1 (Programmed Death-Ligand 1) that
engages PD-1 on chronically activated T cells.3 In the current study, NSCLC tumor aspirations
from six patients undergoing intralesional cisplatinum chemotherapy were examined using multicolor flow cytometry to define the composition of immune cells, their state of activation, and
their expression of PD-1 and PD-L1. We observed that, compared to peripheral blood
mononuclear cells, the tumor infiltrating immune cells manifested elevated numbers of activated
T cells expressing CD25 and CD56, and increased proportions of CD8+ and  T cells. These
studies demonstrate the feasibility of identifying and phenotyping tumor-infiltrating immune
cells using intralesional aspiration and set the stage for future studies using single cell RNAseq
and to potentially develop cell-based immune therapy.
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Introduction
Past research has informed us how cancer intervention treatments such as systematic
chemotherapy and immune checkpoint inhibition (ICI) therapy work to arrest cancer progression.
However, how these treatments affect the tumor-infiltrating immune cell populations remains
understudied. New technology allows chemotherapy to be delivered directly into lung tumors
through bronchoscopic-guided needle injection for patients with few other therapeutic options.
Samples of the tumor’s cellular composition can also be aspirated during this procedure. This
method can be repeated over several weeks to provide directed therapy along with an in-depth
assessment of infiltrating immune cells and cell death. This study aimed to analyze and
understand the composition of immune cells infiltrating non-small cell lung cancer tumors
(NSCLC) as a result of these treatments, including T cells, B cells, neutrophils, and monocytes.
The seminal study that provided the impetus for this experiment analyzed RNAseq across
39 human cancer types for the presence of various immune cells. The researchers found that the
presence of T cells, particularly  T cells and CD8+ T cells, correlated with increased survival,
whereas other immune cells such as macrophages, B cells, and neutrophils were associated with
poor rates of survival.4 However, the limitations of this study were that they used RNA from
tumors and did not analyze for the presence and identification of actual immune cells.
Subsequent studies have also challenged these findings. For example, some reports have found
that the presence of   cells may correlate with reduced survival in cancer patients.5 This may
be due to the activation state of   cells and the different cytokine profiles they may produce.
Under non-inflammatory conditions,   cells have been shown to exhibit tissue homeostatic
properties including promoting wound healing.6 The production of tissue-trophic factors by
  cells during resting conditions may be trophic for tumor growth as well. In another study,
3
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when   cells are activated under inflammatory conditions, the expression of cytokines and
cytolytic machinery is altered and causes these cells to become effective tumor killers.7
Realizing that activated   cells could be effective tumor killers under inflammatory
conditions, conceivably intralesional chemotherapy could induce tumor cell death and secondary
inflammatory conditions that change the composition and activation state of infiltrating immune
cells such as   cells. Inflammatory conditions are well known to be provoked by foreign
microbes expressing Pathogen-Associated Molecular Patterns (PAMPs) that engage various
receptors of the innate immune system. Receptors that could be involved with the induction of an
inflammatory response include Toll-like receptors (TLRs), NLRP (Nucleotide-binding
oligomerization domain, Leucine rich repeat and Pyrin domain containing) receptors that activate
the Inflammasome, the RIG-I (Retinoic acid-inducible gene 1) pathway which detects foreign
RNA and drives type I Interferon production, the cGAS/STING (cyclic GMP-AMP synthase /
Stimulator of Interferon Genes) pathway which detects cytoplasmic DNA, among others. More
recently, it has been observed that DAMPs (Damage-Associated Molecular Patterns) are released
by cell hosts that are damaged, and these are able to trigger the same receptors and promote
inflammation.8 Intralesional chemotherapy could thus induce not only tumor cell death, but also
secondary inflammation, changing the composition and possible activation state of infiltrating
immune cells. These possibilities were examined in this study.
In 2018, the winners of the Nobel Prize for Physiology or Medicine, Drs. James Allison
and Tasuku Honjo, demonstrated their ability to harness the immune system to aid in combatting
various forms of human cancer by defining immune checkpoint blockers cytotoxic T lymphocyte
antigen-4 (CTLA-4) and PD-1. They developed immune checkpoint inhibitor therapy (ICI) in
order to counteract certain pathways used by tumor cells to turn off the immune response, such
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as the use of PD-L1 to inhibit T cells.9 One of the patients in this study (Pt. 75) received ICI
therapy, and this creates an additional layer of analysis to the immune composition of the tumors.
The combination of ICI therapy and chemotherapy may influence the composition of immune
cells infiltrating the tumor cells.
Since NSCLC is the leading cause of cancer related deaths, it is important to understand
what is causing such low rates of survival. ICI therapy has partially improved survival rates in
these patients.2 This could possibly point towards the fact that ICI therapy inhibits PD-1 or
CTLA-4 pathways utilized by tumor-infiltrating leukocytes. These pathways, if uninhibited,
downregulate cytotoxic CD8+ T lymphocytes (CTLs).10 However, only about 20-50% of patients
respond to ICI therapy. This failure to respond may be due to a lack of CTLs in the tumor and/or
reduced ability to present tumor specific antigens.11 The current study analyzed what immune
cells are present in NSCLC tumors and how these populations change with chemotherapy. These
results may inform future investigations into pathways associated with response to ICI therapy.
This NSCLC study was between two UVM-affiliated laboratories directed by Dr. Ralph
Budd, a research immunologist, and Dr. Matthew Kinsey, an interventional pulmonologist. It
sought to define the composition of immune cells in NSCLC and how the composition might
change throughout treatment with sequential intralesional injection of chemotherapy. The results
provide a cataloging of immune cell populations that infiltrate the tumors and their response to
these treatments. The findings might provide insight into correlates with positive or adverse
outcomes and establish the potential for future studies performing single-cell RNAseq analysis of
tumor-infiltrating immune cells.
Two hypotheses in particular were tested: 1) Intralesional delivery of cisplatinum into
tumors will induce cell death of the tumors and possibly recruit immune effector cells. This will
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increase neutrophils and macrophages in these areas to phagocytose the cellular debris. 2) Due to
previous work from the Budd lab showing that in inflamed joints,   cells can kill CD4+ T
cells,12 it is predicted that this trend could occur also within tumors, and that the proportion of
intratumor CD4+ T cells will be inversely proportional to the proportion of   cells.

Materials and Methods
Patients:
This study was approved by the University of Vermont (UVM) Committee on Human
Research in the Medical Sciences (CHRMS 17-075). All patients included in this series had
recurrent lung cancer following radiation therapy. Recurrence was pathologically confirmed.
Each case was presented at the local multidisciplinary tumor board and EBUS-TBNI cisplatinum
was recommended by the respective group. The goal of therapy in all cases was local control,
either due to a local recurrence or with palliative intent for treatment of a non-stentable airway
obstruction.

Patient Tumor Aspirate Procedure:
The endobronchial ultrasound bronchoscope was used to locate the tumor at the region of
interest. The EBUS-TBNA needle was first used to sample the lesion and verify the presence of
a tumor if this region was not previously diagnostically sampled or known to be NSCLC. All
aspirates necessary for clinical care were obtained first. Prior to instillation of the cisplatinum, a
needle biopsy was obtained for research purposes. The 19-gauge EBUS-TBNA needle was then
re-inserted into the tumor. The stylet was removed and a syringe containing 40 ml of 1 mg/ml
cisplatinum was attached. The needle was placed into the lesion and intraoperative cone beam
CT scan was used to verify the location. The dose was then administered with monitoring of the
6
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ultrasound image. As the cisplatinum was injected, the images became increasingly hypoechoic
in the region of distribution of the agent. This procedure was repeated weekly for up to 4 weeks.

Preparation of Peripheral Blood Mononuclear Cells (PBMC) and Patient Tumor Aspirates:
PBMC were prepared from whole blood from a healthy, adult individual, unrelated to the
patients, using standard Ficoll-Hypaque separation by centrifugation. Tumor needle aspirates
were dispensed into RPMI medium containing 10% FCS (Fetal Calf Serum) to keep the cells
healthy until they were analyzed.

Flow cytometry analysis:
Cells were stained with a live/dead vital stain and with antibodies to the following surface
determinants: CD45 (hematopoietic cells), CD66b (neutrophils), CD14 (monocytes), CD19 (B
cells), T cell receptor (TCR)- and TCR-, CD4, CD8, CD25 (high affinity IL-2R), CD56
(natural killer cell activation marker), PD-1 (checkpoint blocker), and PD-L1 (ligand for PD-1).
Samples were passed on an Aurora flow cytometer and analyzed using FloJo software.

Results
Patient information is presented in Table 1. Only one patient was female and had
concomitant ICI therapy. All patients received external beam radiation therapy before their
recurrence. Three out of six patients’ tumors responded to the cisplatinum treatment.
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Table 1: Patient information collected about their demographics, characteristics of their NSCLC, past and current
therapies, PD-L1+ tumor cell proportion, and response to the cisplatinum treatment. Nivolumab is a human IgG4
monoclonal antibody that blocks PD-1.

Analysis of immune cells within tumors was conducted on endobronchial-guided
ultrasound (EBUS) aspirates from non-small cell lung cancers. Figure 1 shows an example of the
process. Tumor aspirates were taken at approximately weekly intervals followed by instillation
of cisplatinum for up to 4 weeks (Figure 1A). Figure 1B illustrates needle placement within
tumors by ultrasound. An example of tumor regression following treatment is shown in Figure
1C.
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Flow cytometric analysis was done on the tumor aspirates using a 12-color panel of
antibodies. Figure 2 shows an example of the identification of the various cell types and
additional functional surface phenotypes using peripheral blood mononuclear cells (PBMC) as a
reference control.
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Analysis of tumor aspirates revealed that most samples held a large proportion of dead
cells (Figure 3). The percentage of dead cells was higher in most samples compared to the
PBMC. CD45+ immune cells (which is expressed by all hematopoietic cells except erythrocytes
and plasma cells) within the tumors were found predominantly in the live cell gate (Figure 3B).

Immune cells could easily be identified from tumor aspirates, including T cells,
monocytes, B cells, and neutrophils (Figure 4). These populations varied among patients, and
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within individual patients over the time of sampling (Figures 5 and 6). The percentage of
neutrophils increased over the course of treatments in four patients (75, 68, 56, 114) (Figure 5A).
This might have been in response to the increased tumor cell death likely occurring with the
sequential cisplatinum treatments. Monocyte levels were also considerably higher in patient
samples compared to the PBMC sample from a healthy individual, whereas the proportion of B
cells was relatively similar to PBMC and fairly constant over time (Figure 5A). The ratios of
lymphocytes (T and B cells) to neutrophils varied considerably during the course of tumor
treatments, largely due to the change in neutrophils over time.
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There was an observable decrease in the proportions of TCR-+ in several patients over
the duration of sampling (Figure 6). In addition, the proportion of CD45+ cells that were  T
cells was considerably higher than in peripheral blood. αβ T cells tended to diminish over the
course of cisplatinum treatments whereas γδ T cells tended to increase in many cases, very
similar to the proportion of neutrophils. This might reflect that TCR-+ and TCR-+ cells
respond to different ligands. Concerning this factor, related studies in the Budd lab using a
soluble TCR- tetramer have shown that the ligand(s) for  T cells are expressed by tumor
cells induced to undergo cell death with staurosporine (Figure 7A). Additional studies revealed
that TCR- ligand was also expressed by CD4+ T cells but not CD8+ T cells in peripheral blood
(Figure 7B) and these  T cells were previously observed to be lytic for CD4+ but not CD8+ T
cells.12 This might help explain the proportion of CD4+ and CD8+ T cells within the tumors (see
below).
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The previously mentioned differences in the proportions of immune cells between PBMC
and tumor aspirates argues that the tumor samples were not merely contaminating peripheral
blood. This notion was further supported by additional surface phenotyping of the immune cell
subsets. In nearly all tumor aspirates the proportion of CD8+ cells was higher than CD4+ cells,
the reverse of which was observed in PBMC (Figure 8A and 8B). In addition, higher levels of
CD25 (IL-2Rα) on CD4+ and CD8+ T cells were seen in tumor samples compared to peripheral
blood (Figures 9B and 9C). The peripheral blood sample revealed that only 0.27% of CD4+ T
cells and 0.17% of CD8+ T cells expressed CD25. The differences between tumor aspirates and
peripheral blood extended to the natural killer cell marker of cytolytic activity, CD56, whose
expression was also considerably higher in tumor T cells than peripheral blood T cells (Figure
9A). These increases in CD25 and CD56 expression by tumor T cells likely reflects their
13
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activated state compared to peripheral blood, suggesting a proliferative dynamic environment of
tumor-resident T cells.
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A feature of many tumor environments is the expression of the checkpoint blocker ligand,
PD-L1, by both tumor and immune cells.13, 14 Consistent with this, we observed that all immune
cells, except monocytes, manifested a higher proportion of PD-L1+ cells than PBMC (Figure
10). In neutrophils, PD-L1 expression tended to decline over the course of treatments in many of
the patients, whereas PD-L1 expression on B cells trended upward in some patients.
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An additional marker of chronic T cell activation is the upregulation of PD-1
expression.15, 16 Both CD4+ and CD8+ tumor-infiltrating lymphocytes expressed markedly
higher levels of PD-1 than the equivalent T cell subsets in PBMC (Figure 11A). Chronically
activated CD8+ T cells also give rise to CD4-CD8- T cells (Figure 11C),17, 18 and this subset was
also apparent in the tumor lymphocytes at a considerably higher proportion of T cells than in
PBMC (Figure 11B). Particularly striking was that the proportion of CD4-CD8- T cells closely
paralleled the levels of PD-1 expression by the CD8+ subset, consistent with their chronicity of
activation.
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Discussion
The current studies demonstrate the feasibility of sampling the tumor microenvironment
over time through sequential needle aspirations of lung cancer nodules. The strikingly different
composition and phenotype of immune cells in these tumor aspirates compared to peripheral
blood mononuclear cells supports the view that the intralesional samples are not merely
contaminating peripheral blood. In addition, the changes in composition of the samples in each
patient upon repeated aspirations suggests modulation of the tumor environment due to instilled
cisplatinum.
As anticipated, there was a considerable amount of cell death in the tumor aspirates.
Several factors could contribute to this. Tumors manifest considerable growth followed often by
spontaneous cell death, which in this case was likely augmented by the instillation of
cisplatinum. There is also the possible shear stress of the aspiration through a small needle, as
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well as some cell loss following the freezing and later thawing of the sample. However, analysis
of the dead cell gates by flow cytometry revealed few, if any, CD45+ immune cells, suggesting
that the vast majority of the dead cells could be tumor cells.
A considerable portion of neutrophils was present in many samples. Neutrophils are
activated by danger signals emanating from dying cells, such as ATP, nucleic acids, and
calreticulin that trigger purinergic receptors, toll-like receptors (TLR7/8/9-MyD88), and
phagocytosis.19 Previous studies have suggested that the presence of these cell types in tumors
correlates with poor outcome.20, 21, 22 Consistent with this view, intratumor neutrophils also
expressed elevated levels of PD-L1, which could engage PD-1 on the infiltrating T cells to
induce cell senescence.
Another cell type whose presence might reflect stressed/dying tumor cells would be  T
cells. Although these T cells reflect only 2-3% of peripheral blood T cells, they reside at
epithelial barriers and accumulate at sites of inflammation during certain infections, autoimmune
conditions such as rheumatoid synovium, and in many tumors. Recent work from the Budd lab
has demonstrated that a soluble TCR- tetramer stained several tumor cell lines, suggesting that
they expressed the ligand(s) for  T cells, and that the ligand was highly expressed by
stressed/dying T cells and exported to the cell surface.23 Consistent with this model, it was
interesting to note that the proportion of  T cells had increased compared to the PBMC sample,
whereas the proportion  T cells decreased. This might reflect the different nature of antigens
and antigen presentation for these two T cell subsets.  T cells require antigen presentation via
MHC restriction on viable antigen-presenting cells, which could be greatly reduced by the
cisplatinum treatments.  T cells, by contrast, are not MHC restricted and respond to ligands
exposed or expressed by stressed or dying cells.
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As this was a pilot exploratory study, it was not possible to include functional immune
assays such as cytokine production, cytolytic activity, or immune cell exhaustion. However,
certain phenotypic signatures suggest potential functions. As one example, some patient samples
revealed opposite trends in the proportion of  versus  T cells. As noted above, this might
reflect the different nature of antigen presentation. The detection of elevated levels of CD56, an
adhesion molecule associated with cytotoxic function of T cells, underscores the potential
functional capacity of the infiltrating T cells compared to peripheral blood T cells. In addition, an
inverse CD4/CD8 ratio was observed in several tumor samples (greater proportion of CD8+ T
cells in tumors versus greater percent of CD4+ T cells in peripheral blood). This could reflect
either selectively increased CD8 T cell expansion within the tumors or preferential CD4 T cell
death, or both. Along these lines, work from the Budd lab has previously shown that  T cells
are preferentially cytolytic to activated CD4+ T cells over CD8+ T cells.12 This is consistent with
more recent findings that the ligand for  T cells is expressed more by CD4+ T cells than CD8+
T cells.23 In addition, the increased expression of CD25 (the high affinity IL-2R) would suggest
that a portion of the tumor T cells were activated and proliferating. Although CD25 expression
on CD4+ T cells can reflect the presence of inhibitory regulatory T cells,24 CD25 expression on
CD8+ T cells likely reflects their activation. The upregulation of PD-1 on T cells in some
samples is consistent with the interpretation of chronic T cell activation.15, 16 A further indication
of CD8+ T cell proliferation is the existence of CD4-CD8- TCR-+ cells in the tumor aspirates.
As discussed in more detail below, this subset arises from CD8+ precursors during chronic
antigen stimulation.17, 18
Concomitant ICI therapy with cisplatinum treatment was administered to patient 75, and
an abrupt decline in PD-1 expression was observed on CD4+ and CD8+ cells following week 1.
19
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This could be explained by the fact that Nivolumab is an anti-PD-1 antibody, which could block
binding of the anti-PD-1 antibody used for flow cytometry. Alternatively, Nivolumab could
induce depletion of PD-1+ cells through complement-mediated lysis, Fc Receptor uptake, or
other means.
The tumor microenvironment is notorious for inhibiting the development of an effective
immune response. Several conditions tend to render T cells less responsive or “exhausted” under
these harsh conditions. Among these are limited nutrients (tumors are often highly glycolytic)
and hypoxia. Resting T cells undergo a burst of glycolysis following their activation to become
effector T cells.25, 26 In conditions of low glucose or downregulation of the glucose transporter
Glut1, T cells do not convert to effector T cells efficiently.27, 28 In addition, the hypoxic tumor
environment induces the transcription factors HIF-1 and NFAT in T cells, the upregulation of
PD-1, as well as enlarged mitochondria with disrupted cristae.29, 30 These collectively lead to a T
cell senescent state.31 The high levels of the checkpoint blocker, PD-1, on both tumor-infiltrating
CD4+ and CD8+ T cells in this current study reflects this condition. Recent reports have
demonstrated the ability to reverse this exhausted state by administration of metformin, an FDAapproved drug for the treatment of diabetes. Metformin has potent immunomodulatory effects on
immune cells, and it also inhibits oxygen consumption in certain tumors.32 For example, in a
murine glioblastoma model, metformin was shown to significantly prolong tumor-free survival,
and this efficacy was completely dependent on the presence of  T cells.32
Many of these same features of intratumor T cell exhaustion have also been previously
described in CD4-CD8- TCR-+ cells, which were present in the tumor samples, and also
occur in human and murine lupus.16, 33, 34, 35 The presence of CD4-CD8- TCR-+ cells in many
of the patient samples likely reflects chronic T cell activation, particularly of CD8+ T cells.
20

IMMUNE CELL COMPOSITION IN NSCLC TUMORS
CD4-CD8- T cells also accumulate in mice and humans bearing a mutation in the death receptor
gene Fas (CD95).33, 36 Studies have shown that this subset arises from CD8+ precursors
undergoing progressive rounds of homeostatic proliferation. In the process, CD4-CD8- T cells
manifest several of the same features that have been described for exhausted tumor infiltrating
lymphocytes in hypoxic conditions. This includes upregulation of PD-1, enlarged mitochondria
with disrupted cristae, and upregulation of the transcription factor NFAT.16, 37 As such, the
presence of the same CD4-CD8- T cells in the tumors of this study likely represent sensitive
surrogates for the presence of T cell proliferation and exhaustion. The fact that the proportions of
CD4-CD8- T cells closely paralleled the proportion of CD4+ and CD8+ T cells expressing PD-1
serves as an independent confirmation that these phenotypes reflect the exhaustive environment
within these tumors.
The largest limitation of this study was that there were only 6 patients sampled. The
number of patients with recurrent NSCLC willing to undergo cisplatinum treatments and EBUSTBNA are limited. To create more data that could be fairly tested with statistical analyses, this
would have to be done over a larger length of time, such as a few years, to allow for sufficient
collection of such specific patient data. A goal within this collection would be to get as even of a
gender ratio in the patients as possible seeing that only one female patient provided data in this
study. With just 6 patients, our results were limited to mostly observational analyses. However,
this study paves the way to further work in the area. Another limitation was that since this was a
pilot exploratory study, it did not include functional immune assays such as cytokine production,
cytolytic activity, or immune cell exhaustion. As a result, other alternative phenotypic signatures
were relied on to comment on discussed potential functions.
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Future studies could extend this work by using single-cell RNAseq to help define the true
functional potential of the immune cells and would include measurements of cytokines and
cytolytic machinery. In addition, the soluble TCR- tetramer developed in Dr. Budd’s group
could be used to histologically stain various tumor samples to determine which ones express
TCR- ligands, and, as a result, be potentially sensitive to  T cell therapy. Regarding ICI
therapy, gathering data on more patients undergoing cisplatinum and ICI therapy would allow for
more concrete interpretations on the effect of these therapies, together, on the immune cell
populations within NSCLC tumors.
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